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ABSTRACT 
CRISPR-Cas provides prokaryotes with adaptive immunity from bacteriophage and 
other MGEs (mobile genetic elements).  CRISPR-Cas systems use a crRNA-guided effector 
complex to specifically target and destroy invading nucleic acids. These immune systems are 
immensely diverse among the six types, and often within subtypes.  Whereas most types of 
CRISPR-Cas target foreign DNA, Type III systems (Csm/Cmr) utilize a transcription-
coupled mechanism to target RNA.  Upon target RNA binding, the Type III effector degrades 
both RNA and DNA and produces a secondary messenger that activates a trans-acting 
RNase.  To prevent inappropriate activation by host-derived targets, effector activity is 
dependent upon identification of the target’s origin, which is signaled by the nucleotides 
most adjacent to the targeted sequence.  Two mechanisms for this identification have been 
described in two subtypes of Type III systems.  The complex may specifically recognize 
these sequences, or a host-derived sequence may base pair with the crRNA tag.  It is 
currently unknown if the mechanism used by a given effector is subtype- or species-specific.   
Contrary to data available for most other CRISPR-Cas systems, it has been suggested 
that Type III effectors are extremely tolerant of mismatches.  The data supporting this is 
sparse, but mismatch tolerance has been demonstrated in one subtype of Type III.  It is also 
unknown if this is a subtype- or species-specific characteristic. 
Here we utilize recombinantly purified Thermotoga maritima Cmr (TmaCmr) 
complex and RNA targets generated by in vitro transcription to systematically explore these 
questions.  We demonstrate that both mechanisms are utilized by TmaCmr to identify host-
derived transcripts.  We also show that TmaCmr is extremely tolerant of mismatches.  These 
results unify the features of the two major subtypes of Type III CRISPR-Cas systems. 
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CHAPTER 1: CRISPR-CAS IMMUNITY 
 
Viruses are ancient, ubiquitous, and diverse, surviving in all environments on Earth 
and infecting every known living organism1.  Although not considered living, they are among 
the most successful biological entities, and are proposed to be the precursor to life1. Viruses 
that infect prokaryotes, known as bacteriophage (or simply phages), are incredibly numerous 
with an estimated population of 1031, making bacteriophages the most abundant biological 
units on Earth2,3.  Genetic diversity among bacteriophages is extraordinarily high, due to their 
long evolutionary history and the relative ease by which recombination and horizontal gene 
transfer can occur among such a vast population2.  Prokaryotes and phages have coevolved 
over billions of years, each exerting selective pressure on the other and driving dynamic 
genetic change in their counterpart3.  In a classic example of the Red Queen hypothesis, 
phages drive prokaryotes to evolve in order to avoid extinction, which in turn drives phages 
to counter-adapt to avoid their own demise4,5.  
Prokaryotic defense mechanisms 
In order to survive a diverse bacteriophage population that outnumbers their own ten 
to one5, prokaryotes have developed numerous forms of defense in order to protect 
themselves from viral invasion.  The number of defense systems within prokaryotic genomes 
correlates more or less linearly with the size of the genome; the larger the genome, the more 
genes dedicated to protecting it6.  Prokaryotic defense mechanisms fall into four main 
categories: invasion resistance, inhibition of phage replication, programmed dormancy or cell 
death, and immunity (Figure 1).  The first line of bacterial defense, invasion resistance, 
  
 2 
includes mechanisms by which bacteria prevent a virus from binding to the bacterial cell or 
from successfully injecting its genetic material; these strategies include reducing the 
expression of, altering, or blocking the bacterial receptor to which the phage adheres, as well 
as altering, blocking, or inhibiting the formation of the nucleic acid injection site3,6.  Bacteria 
have also developed a wide array of mechanisms to prevent a bacteriophage from replicating, 
including blocking phage DNA integration or replication, inhibiting phage transcription, and 
preventing phage particle packaging or release3,7.  
If these and other immune strategies fail, an infected bacterium may become dormant 
or undergo programmed cell death in an attempt to confine the infection and protect the 
larger population. This is typically achieved through systems that inhibit essential cellular 
processes, either by inducing expression of a host protein that directly interferes with a 
metabolic process (abortive infection systems), or by inducing degradation of an antitoxin, 
which is required for repression of a toxin that interferes with one of a diverse group of 
cellular processes (toxin-antitoxin systems)3,6,7.  These strategies are considered altruistic as 
they sacrifice the individual in order to preserve the population7.  
While dormancy or programmed cell death may help to prevent the spread of a 
bacteriophage among a population of bacteria, many prokaryotes have developed immune 
responses to defeat phage infections while avoiding cellular suicide.  Immune systems 
involve destruction of invading nucleic acid and may be innate or adaptive3,6.  Innate 
immunity, such as restriction-modification systems and likely argonaute-mediated systems, 
provides a nonspecific response to foreign genetic material.  Restriction-modification 
systems encode a methyltransferase, which methylates host DNA, and an endonuclease (also 
called restriction enzyme), which cleaves unmethylated (foreign) DNA at sequence-specific 
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locations3.  Previously thought to exist only in eukaryotes, recently discovered prokaryotic 
argonautes are proposed to serve as phage-defense systems by destroying foreign nucleic 
acid in a DNA or RNA guide-dependent manner; however, it is currently unclear how these 
guides are generated and no studies have yet confirmed this function3,8.  Adaptive immune 
systems provide the host with a memory of prior infection in order to generate a specific 
response in the event of subsequent viral invasion.  In the only known prokaryotic adaptive 
immune system, CRISPR-Cas, clustered regularly interspaced short palindromic repeat 
(CRISPR) arrays serve as a memory bank of previous viral encounters, providing RNA 
guides for the CRISPR-associated (Cas) nucleases3.  
CRISPR-Cas Immunity 
A CRISPR locus contains Cas genes and a CRISPR array, which consists of the 
promoter-containing leader sequence, foreign-derived sequences (called spacers) interspersed 
with identical host sequences (called repeats)9,10.  These repeating sequences were first 
reported in 198711 and spacer sequences were shown to be derived from mobile genetic 
elements (MGEs) in 2005, implicating a role for these systems in adaptive immunity12–14.  
This role was confirmed two years later when it was shown that new spacers derived from 
phage were incorporated into CRISPR arrays following phage challenge; with Cas genes, 
these spacers conferred resistance to subsequent phage infections9.  This is accomplished 
through an RNA-guided effector complex; spacers are transcribed to form guide CRISPR-
RNAs (crRNAs), which direct Cas nucleases to cognate nucleic acid sequences for 
destruction15 (Figure 2).  
CRISPR-Cas systems are found in about 50% of sequenced bacterial genomes and 
nearly 90% of archaea, and are nearly ubiquitous in hyperthermophiles6,16.  There is 
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incredible diversity among CRISPR-Cas systems; although the ability to acquire new 
sequences makes CRISPR-Cas a relatively adaptable defense system, the constant evolution 
of phages creates the need for diversity among defense systems nonetheless3,4.  As such, gene 
composition, effector complex organization, and mechanisms of interference vary widely 
among CRISPR-Cas systems.  To date, two classes (1 and 2), six types (I-VI), and more than 
20 subtypes of CRISPR-Cas interference systems have been identified15.  Classes are defined 
by the organization of the interference complex; Class 1 complexes consist of a crRNA and 
multiple proteins, while Class 2 complexes contain a single guide RNA-bound protein10,15. 
Classification into the different types and subtypes is based on a number of factors, including 
the signature genes of each type/subtype, Cas protein sequence homology, locus architecture, 
and phylogeny of Cas1, the most conserved Cas protein15.  Figure 3 summarizes the 
important features of each CRISPR-Cas type. 
Cas1, found in all six types of CRISPR-Cas systems, is one of the key players in 
spacer acquisition, the first step of CRISPR-Cas immunity15,17 (Figure 2).  The acquisition 
complex is typically formed by a heterohexameric complex of four catalytic Cas1 subunits 
and two Cas2 subunits, which perform a structural function10,17.  This acquisition machinery 
is responsible for capturing foreign DNA (protospacers) and integrating them as new spacers 
in the CRISPR array.  Cas1-Cas2 binds fragments of viral DNA that contain a specific 
sequence called a protospacer adjacent motif (PAM), which does not exist within the 
CRISPR array17.  These fragments are likely produced by DNA repair machinery; the free 
dsDNA end (which typically signal a double strand break in circular bacterial genomes) of 
the viral DNA recruits RecBCD, which resects the ends, producing short pieces of DNA17.  
Upon protospacer capture, the Cas1-Cas2 complex inserts the protospacer adjacent to the 
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first repeat by catalyzing two cleavage-ligation reactions17.  This places the new spacer at the 
leader end of the array, thus imparting a chronological history of infection; this placement 
(nearest the promoter) likely provides more robust generation of the crRNA that targets the 
most recent invader, which tends to be the cell’s biggest threat17,18.  There are two modes of 
acquisition: naïve acquisition, in which new spacers are incorporated, and primed acquisition 
(or simply priming), which incorporates spacers that share homology with existing spacers17.  
Priming provides an enhanced rate of acquisition (relative to naïve acquisition)17.  This 
reduces viral escape in two ways; priming stimulates integration of targets in the event of 
viral mutation and allows for insertion of a copy of an existing spacer nearer to the promoter 
to allow for more robust crRNA generation17,19. 
The second step of CRISPR-Cas immunity is crRNA generation (Figure 2).  The 
CRISPR array typically contains one transcription start site within the leader sequence, thus 
producing a single precursor crRNA (pre-crRNA).  The pre-crRNA is processed to generate 
multiple mature crRNAs through endonucleolytic cleavage within the repeat sequences10.  
The nucleases involved in crRNA maturation vary; in some types of CRISPR systems, the 
processing nuclease is part of the interference complex, while in others this function is 
performed by a trans-acting Cas or non-Cas nuclease10,15.  Mature crRNAs consist of a small 
segment of repeat sequence on the 5’ end, referred to as the 5’ tag (or crRNA tag), followed 
by the spacer sequence.  Cas proteins identify the tag to assemble around the crRNA, and the 
spacer within the crRNA guides the complex to its targets to complete the final step of 
immunity: interference (Figure 2). 
CRISPR complexes may be guided by their crRNA to cognate DNA, as in Types I, II, 
V, and likely IV, or cognate RNA, as in Types III and VI15.  Some interference complexes 
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are also capable of degrading collateral nucleic acids upon binding to targets; a nonspecific 
DNA nuclease domain is activated in Type III complexes upon target binding, while target 
binding in Type VI complexes activates a second, nonspecific RNA nuclease domain15,20,21.  
To avoid inappropriate targeting, a proper target must be complementary to the crRNA and 
must be identified as foreign in origin in order to activate the interference complex.  A 
crRNA is naturally complementary to the DNA from which it is derived; thus DNA-targeting 
complexes must confirm the target is foreign DNA to avoid destruction of the host genome 
(autoimmunity).  To this end, complexes in Types I, II, and V identify foreign sequences by a 
specific protospacer adjacent motif (PAM), which is a short sequence that is not found in the 
CRISPR array10.  Similarly, RNA-targeting complexes must avoid activation by anti-
CRISPR transcripts, which can arise from the anti-sense transcription of a CRISPR array22.  
In Types III and VI, complementarity between the tag of the crRNA and the protospacer 
flanking site (PFS) is a signal of host transcript and prevents interference complex 
activation20,23.  Host target binding in Type VI prevents both targeted and collateral RNA 
cleavage20, while in Type III, host target RNA is cleaved and only collateral DNA cleavage 
is inhibited23. 
Class 1 CRISPR-Cas interference 
While performing similar functions in a crRNA-guided manner, CRISPR-Cas 
interference complexes themselves are quite diverse.  Class 1 effector complexes are 
composed of multiple proteins, typically four to seven subunits in an uneven stoichiometry, 
bound to the crRNA guide24.  Class 1 systems are considered the evolutionary ancestors of 
CRISPR-Cas; genomics studies indicate that the ancestral Cas effector likely utilized a 
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progenitor of the Type III Cas10 subunit24. Class 1 systems are widespread in both archaea 
and bacteria. 
Type I CRISPR-Cas interference 
 
Type I CRISPR-Cas systems are the most common, accounting for about 60% of 
sequenced CRISPR-Cas systems in both bacteria and archaea16.  With at least seven 
subtypes, they are also most diverse6.  The subunits of the Type I complex, Cascade 
(CRISPR-associated complex for antiviral defense), are so diverse among the subtypes that 
subunit homology is often established based on function, rather than sequence10,16.  However, 
the overall architecture and function of the Type I interference machinery is conserved.  The 
pre-crRNA forms stem-loop structures with the repeat, which are recognized by Cas6 for 
crRNA maturation10.  After processing the crRNA, Cas6 remains bound to the hairpin on the 
3’ end, while Cas5 and Cas8 (the large subunit) cap the 5’ repeat10,25.  Multiple Cas7 subunits 
filament along the crRNA, each with a palm domain to stabilizing five nucleotides of the 
crRNA backbone and a thumb domain that kinks the crRNA at every sixth nucleotide; this 
allows for efficient base pairing between the crRNA and target25.  Two copies of Cas11 (the 
small subunit) interact with the Cas7 subunits to stabilize the nontarget strand10.  There are 
many subtype-specific differences in the Type I interference machinery (for example, in 
several subtypes, the small subunit is fused to or functionally replaced by the large subunit), 
but the overall structure of each tends to resemble a seahorse, with Cas6 forming the head, 




 Cascade scans double-stranded DNA for PAM sequences; the large subunit 
recognizes PAM and melts a small region of the duplex10.  This local unwinding exposes a 
small region of single-stranded DNA near the identified PAM, which allows the crRNA to 
sample for complementarity.  If the DNA is not complementary to the first eight nucleotides 
(called the seed sequence) of the crRNA, Cascade dissociates and continues scanning for 
PAM.  Upon identifying a target with complementarity to the crRNA seed, Cascade 
directionally unwinds the DNA.  The target strand forms a duplex with the crRNA and the 
nontarget strand is held by the small subunit to stabilize the subsequent R-loop10,26.  Cascade 
recruits a trans-acting helicase-nuclease, Cas3, which nicks the displaced nontarget strand26.  
Cas3 then undergoes a conformational change that activates the helicase domain and 
translocates and degrades 200-300 nucleotides of DNA10,26.  Another Cas or non-Cas 
nuclease may further degrade the target genome10.  A schematic summary of Type I 
interference can be found in Figure 4A. 
Type III CRISPR-Cas interference 
 
Type III CRISPR-Cas systems account for 34% and 25% of sequenced CRISPR-Cas 
systems in archaea and bacteria, respectively16.  There are four characterized subtypes15.  
Although not as prevalent as Type I systems, with three separate nuclease functions, it is the 
most complex of the CRISPR-Cas types.  While functionally distinct, Type III effector 
complexes, called Csm or Cmr depending on the subtype, are structurally similar to Cascade.   
Like in Type I systems, pre-crRNA is processed by Cas6, which identifies the repeat 
sequence and cleaves eight nucleotides upstream of the spacer, leaving each crRNA with a 
segment of repeat (the crRNA tag) on the 5’ end27.  However, Cas6 dissociates from mature 
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crRNA and is not a part of Type III effector complexes21.  In most subtypes, further 
processing by host nucleases removes repeat sequence from the 3’ end of the crRNA, leaving 
a mature crRNA with just a 5’ tag and a spacer28.  Csm4/Cmr3 and the large subunit, Cas10, 
surround the tag10.  Csm3/Cmr4 form the backbone and filament on the crRNA spacer, with 
multiple copies of the small subunit, Csm2/Cmr5, at the belly.  Like in Cascade, the thumb 
domains of the backbone subunits protrude into the crRNA spacer, flipping out every sixth 
nucleotide29.  The number of backbone and small subunits in the complex depends on the 
length of the crRNA28.  The 3’ end of the crRNA is capped either by Csm5 or by Cmr1 and 
Cmr621,28. 
The Csm/Cmr complex binds to RNA targets that are complementary to the crRNA 
within the complex.  Data suggest that target RNA:crRNA duplex formation does not rely 
upon a seed region30.  Foreign target binding induces a conformational change and initiates 
three enzymatic activities within the complex simultaneously21,28,31–33 (Figure 4B).  (1) The 
Csm3/Cmr4 subunits cleave the bound RNA target at six nucleotide intervals21,28.  (2) The 
HD domain of the Cas10 subunit is activated to nonspecifically degrade adjacent single-
stranded DNA by cleaving after thymine residues21,28. (3) The Palm domain of Cas10 is 
activated to convert ATP to cyclic oligoadenylate (cOA), which acts as a secondary 
messenger31,32.  A fourth enzymatic function, this one outside of the complex, is then 
activated by cOA production; upon binding to cOA, Csm6/Csx1 is activated to 
nonspecifically degrade RNA31,32.  The binding site for cOA is within the CARF domain 
(CRISPR-Cas associated Rossman fold) of Csm6/Csx131,32. The functions of other CARF 
domain proteins, many of which are associated with Type III CRISPR-Cas systems (and 
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some with Type I), are unknown34, but it is likely that these could be regulated by cOA as 
well.   
The proposed model is that Type III CRISPR-Cas interference occurs during 
transcription21,28.  The Csm/Cmr complex may bind to a complementary transcript as it is 
being produced by RNA polymerase; this would provide access to both the RNA target and 
foreign ssDNA within the transcription bubble21,28.  The complex is temporally regulated by 
RNA target degradation and dissociation; thus when the transcript is cleared from the 
complex, the structure reverts to its original conformation, and cOA production and DNA 
cleavage cease22,35,36.  This minimizes the likelihood of off-target DNA cleavage. 
The ability to identify host-derived transcripts also helps Csm/Cmr to avoid off-target 
DNA cleavage.  RNA cleavage by Csm/Cmr requires complementarity between the crRNA 
spacer and target protospacer, and proceeds regardless of transcript origin36.  However, 
identification of self RNAs locks the Cas10 in an inactive state, preventing activation of the 
HD and Palm domains (and therefore cOA production and DNA cleavage)33. While it is 
unknown how prevalent host-derived transcripts might be, they could conceivably arise from 
the antisense transcription of the CRISPR array, particularly if a viral promoter was 
incorporated as a spacer22.  While, like a target RNA, the protospacer of these transcripts 
would be complementary to the crRNA spacer, the 3’ protospacer flanking site (PFS) would 
also be complementary to the crRNA tag; this complementary PFS is called an anti-tag.  
Foreign transcripts do not contain anti-tag sequences, which makes this a good method by 
which to distinguish host from foreign RNA.  This discrimination may occur by two 
mechanisms: identification of the anti-tag sequence37 or base pairing between the anti-tag and 
tag sequences30,38.  
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Type IV CRISPR-Cas interference 
There is little known about Type IV CRISPR-Cas systems.  This single subtype 
system is rare, making up less than 2% of CRISPR-Cas loci16.  Type IV loci are often found 
on plasmids and are often not adjacent to a CRISPR array16.  These loci also lack adaptation 
machinery15.  It is thought that Type IV systems target DNA15; however thus far, no 
experimental interference data are available.  A recent study on the assembly of a Type IV 
complex provides insight into crRNA processing and the structure of the effector (Figure 
4C).  A Cas6-like nuclease, Csf5, cleaves the pre-crRNA, leaving a repeat tag at the 5’ end of 
the crRNA and a hairpin on the 3’ end39.  Csf5 remains bound to the 3’ end of the crRNA and 
Csf2 forms the backbone of the complex39.  Csf1 is the large subunit homolog, and Csf3 
forms the 5’ cap on the crRNA39.   
Class 2 CRISPR-Cas interference  
 Class 2 CRISPR-Cas systems account for less than 15% of bacterial CRISPR loci and 
are rarely found in archaea16.  Containing a single bilobed protein, Class 2 effectors are 
simpler than Class 1 complexes15.  Due to their simplicity, these crRNA-directed nucleases 
have garnered much interest for their utility in molecular biology and biotechnology40. 
Type II CRISPR-Cas interference 
 The three subtypes of Type II CRISPR-Cas systems together make up about 13% of 
bacterial CRISPR loci16.  Type II has been found in only one archaeon15,16. Although not 
found in a great many organisms (5% of all bacteria utilize this immune system41), the 
simplicity of Type II systems and their consequent utility as a programmable biological tool 
has made them the subject of extensive studies.  These effectors are made of a single protein, 
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Cas9, and two RNA guides42.  Like all CRISPR-Cas systems, Cas9 requires crRNA to 
identify complementary targets, but a trans-activating crRNA (tracrRNA) is also required for 
crRNA maturation and target cleavage.  The tracrRNA is encoded within or near the CRISPR 
array and is complementary to the crRNA repeat43.  Prior to processing the pre-crRNA and 
tracrRNA form a duplex, which is recognized and bound by Cas9; this leads to the 
recruitment of a bacterial nuclease, RNase III, which cleaves within the RNA duplex, and a 
second unknown nuclease that removes the 5’ segment of repeat to complete crRNA 
maturation10.   
Assembly of Class 1 effectors requires the presence of crRNA around which the 
individual subunits scaffold, but as Class 1 effectors are single proteins and do not require 
such assembly, they must be held in a catalytically inactive conformation until the guide 
RNA duplex is bound15,42.  Loading of tracrRNA:crRNA induces a dramatic conformation 
change that creates a channel to accommodate target DNA and rearranges the C-terminal 
domain (CTD), which is disordered in the unbound state26,42.  The guide RNA resides within 
a positively-charged groove between the two lobes of Cas9: the recognition (REC) lobe and 
the nuclease (NUC) lobe24.  Unlike Class 1 effectors, which preorder the entirety of the 
crRNA for duplex formation, Cas9 only preorders the 10-12 nucleotides in the seed region, 
likely due to topological constraints (which are relieved in Class 1 complexes by the flipped 
out nucleotides and helical structure)42.  The alpha-helical REC lobe interacts with the 
crRNA:target DNA duplex, while the NUC lobe contains two nuclease domains, RuvC and 
HNH26. 
Much like Cascade, Cas9 scans dsDNA for PAM; sequences are interrogated by the 
CTD and recognition leads to unwinding of the dsDNA adjacent to the PAM42.  The 
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preordered seed region can then probe the PAM-proximal nucleotides, and complementarity 
within the seed prompts a conformation changes within Cas9 to allow full duplex formation 
with the target and to stabilize the resulting R-loop10.  Further complementarity induces yet 
another conformation change that activates the HNH nuclease domain to cleave the target 
strand and allosterically activates the RuvC nuclease domain to cleave the nontarget strand26.  
These concerted cleavage events lead to a double-strand break located three base pairs 
upstream of the PAM sequence10 (Figure 5A). 
Type V CRISPR-Cas interference 
Type V immunity is rare, representing less than 2% of CRISPR-Cas systems16,41.   
Nevertheless, Type V systems are quite diverse and ten subtypes have been proposed44.  The 
effector proteins from these subtypes, Cas12, are quite diverse but have conserved catalytic 
motifs associated with a RuvC-like endonuclease domain; due to this domain and some 
functional similarities, Type V systems were originally classified as a subtype of Type II 
CRISPR-Cas15,16.  However outside of the shared nuclease motifs, Cas12 and Cas9 proteins 
share no sequence or structural homology and it is now thought that Type II and Type V 
evolved separately to converge upon a similar function15.  In fact, because of the diversity 
within the RuvC-like domains (as well as throughout the rest of the proteins), it is likely that 
many subtypes of Type V also evolved independently from multiple transposon-encoded 
nucleases10,44.  Support for this theory was recently demonstrated in a study that included 
both metagenomic analysis of CRISPR-Cas systems and biochemical analysis of several 
functionally diverse Type V systems44.  Most Cas12 effectors are thought to target dsDNA, 
generating a double-strand break and further degradation of each strand, but this study 
demonstrated RNA targeting with collateral RNA and ssDNA degradation in one particular 
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subtype, as well as dsDNA nicking in another44. The model described below is based largely 
on Cas12a (of Type V-A), the most well studied Type V effector (see also Figure 5B). 
About half of Type V subtypes utilize a tracrRNA44.  Dual nuclease activity allows 
Cas12 (with tracrRNA where required) to process pre-crRNA10,44.  Like Cas9, Type V 
effector proteins are inactive until bound to their guide RNAs26.  A conformation change 
induced by guide RNA binding allows Cas12 to search for PAM, and upon recognition, 
locally unwind the dsDNA to expose the first five nucleotides and test for seed 
complementarity45.  The rest of the R-loop is then formed and a conformational change leads 
to the opening of a catalytic pocket45.  A single active site creates two successive nicks, one 
on each strand of the DNA target, generating a staggered break in the dsDNA and leaving 
short 5’ overhangs15,44,46.  Both the target and nontarget strand can then be degraded as the 
conformational change induced upon target binding enables nonspecific ssDNA shredding by 
the same domain46.  The conformation of Cas12 does not revert to the pre-activated state as 
long as the R-loop remains bound, leaving the catalytic pocket open to complete destruction 
of the bound target or any adjacent ssDNA45,46.  The nontarget strand is cut much more 
efficiently than the target strand due to its positioning within the catalytic pocket, which 
allows the R-loop to persist for extensive ssDNA degradation45.  The effector conformation is 
reset upon crRNA displacement; a new crRNA molecule replaces the crRNA:target duplex, 
reverting Cas12 to its inactive state45.   
Type VI CRISPR-Cas interference 
  Type VI is the most recently identified CRISPR-Cas system47.  It represents 
less than 1% of CRISPR-Cas loci in sequenced bacterial genomes and has not been found in 
archaea41.  Four subtypes of Type VI systems have been proposed15,48.  These exhibit great 
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diversity; the effector, Cas13, and in particular the two HEPN domains that define Type VI 
systems, show even greater sequence divergence than the other Class 2 systems15.  Like 
Cas12, Cas13 also processes the pre-crRNA; however none of the Type VI subtypes require 
a tracrRNA10,15.  The crRNA is bound within a cleft of the bilobed structure that is common 
to Class 1 effectors48; upon its binding, Cas13 undergoes a conformational change to permit 
duplex formation between the crRNA and target RNA10.  Cas13 does not require a PAM 
sequence, and instead relies on the PFS for host target identification10,20.  Additionally, Cas13 
does not utilize a canonical seed sequence, but does require a minimum complementarity 
between crRNA and RNA target48. 
Target identification induces a conformational change that brings the active site 
residues of the two HEPN domains into proximity with one another, forming a bipartite 
active site that faces the exterior of the protein48.  This solvent-exposed RNase active site 
readily degrades the bound target and other adjacent RNAs10,48 (Figure 5C).  The 
indiscriminate RNA cleavage has been shown to degrade host RNAs and restrict bacterial 
growth in heterologous systems; this indicates that Type VI effectors may induce dormancy 
or cell death or that the natural host employs other strategies to keep this RNA degradation in 
check10. 
Unlike Type III systems which degrade self RNA targets but inhibit the collateral 
DNase activity in their presence, complex formation between the Cas13 crRNA and a self 
RNA target leads to inhibition of both specific and nonspecific RNA cleavage20.  The 
identification of self RNA occurs at the PFS, with some systems requiring specific sequences 
in the 3’ PFS (adjacent to the crRNA tag) and some seeming to have requirements in both 5’ 
and 3’ PFS10.  It has been demonstrated in one subtype that the mechanism of PFS 
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identification is through tag:antitag complementarity and proposed that this could be a 
universal mechanism of  self sequence identification by Type VI effectors20.  Some Type VI 
effectors do not require processing of their crRNA, which would leave repeat sequence on 
both sides of the spacer10; this may explain why some subtypes have a sequence requirement 








Figure 1.  Mechanisms of phage resistance in prokaryotes.  (1) By preventing a phage from adhering 
to the cell surface or injecting its genetic material, invasion is resisted.  (2) The ability to destroy 
nucleic acid provides adaptive or innate immunity.  (3) Preventing viral transcription, translation, or 
packaging, inhibits viral replication.  (4) To prevent spread of the phage and protect surrounding 




4. Induce dormancy 







Figure 2.  General mechanism of CRISPR-Cas immunity.  Acquisition: the process by which new 
spacers are incorporated into the CRISPR array.  (1) Fragments of viral DNA are produced, likely 
via end resection by the host RecBCD.  These fragments are captured by the acquisition machinery, 
Cas1-Cas2.  (2) The fragment is inserted into the CRISPR array and becomes the leader-proximal 
spacer to provide immunity upon repeat phage exposure.  crRNA generation: the process by which 
the crRNA guides are produced (3) Transcription is initiated at the transcription start site within the 
leader sequence and a single RNA, the pre-crRNA, is produced.  (4) The crRNA is processed by Cas 
or other host nucleases to produce a mature crRNA around which the CRISPR-Cas effector complex 
forms.  Interference: the targeting and destruction of specified viral sequences. (5) The crRNA 
guides the effector complex to viral targets.  Activation of the effector complex requires verification 
that the target is of foreign origin (e.g. by identifying the PAM sequence) and complementarity 
between the crRNA and the target protospacer.  Upon activation, the effector cleaves the target.  See 

























Figure 3.  Defining characteristics and features of the six CRISPR-Cas types.  Italics indicate 
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Figure 4. Class 1 interference. (A) Type II. Upon PAM recognition, Cascade melts the DNA to 
identify targets complementary to the crRNA.  Target identification leads to the recruitment of Cas3, 
a trans-acting helicase/nuclease, which degrades the ssDNA. (B) Type III. The Csm/Cmr complex 
binds to and determines the origin (via the PFS) of complementary RNA targets. Foreign target 
binding leads to the activation of the three enzymatic functions of Csm/Cmr: (1) RNA is cleaved by 
the Csm3/Cmr4 subunits (2) adjacent ssDNA is cleaved by Cas10 in a sequence nonspecific manner, 
and (3) cOA is produced by Cas 10. A trans-acting RNase, Csm6/Csx1, is activated upon cOA 
binding and nonspecifically degrades RNA. (C) Type IV (proposed structure). The stoichiometry of 










































Figure 5. Class 2 interference. (A) Type II. Both crRNA processing and interference require 
tracrRNA, which consists of several hairpins and a region of complementarity to the crRNA tag; 
these two together form the RNA guide for the Type II effector, Cas9. Cas9 searches for PAM 
sequences and then melts adjacent dsDNA.  Complementarity between the crRNA and target prompts 
the two nuclease domains of Cas9 to nick each strand of the DNA, creating a double-strand break. 
This break is then degraded by host nucleases. (B) Type V. This type exhibits extreme functional 
diversity, which is just now being uncovered; thus one subtype is represented here (Cas12a). The 
complex searches for PAM sequences and melts adjacent dsDNA.  Complementarity between the 
crRNA spacer and target protospacer activates the nuclease domain to cleave both target and 
nontarget DNA strands, generating a staggered break. This nuclease degrades both strands, as well as 
any adjacent ssDNA.(C) Type VI. The complex targets complementary RNA, which Cas13 identifies 
as a foreign transcript by its PFS.  This activates the RNase domain, which degrades both the target 
















Type III CRISPR-Cas systems offer robust protection from phage by utilizing a 
CRISPR-RNA (crRNA)-guided effector complex to degrade foreign RNA and DNA.  The 
ability of these complexes to correctly identify RNA is essential for appropriate activation of 
the DNA degradation domain; this regulation is key to avoiding both autoimmunity 
(degradation of the host genome due to an incorrect signal) and immune suppression 
(successful invasion of phage due to deficient degradation).  Two different mechanisms of 
self RNA identification have been described in Type III CRISPR-Cas systems: multiple type 
III-A studies have shown that self RNAs are recognized by base pairing between the target 
antitag and crRNA tag sequences, while a type III-B study indicated sequence-specific 
recognition of the RNA PFS.  Here, we present evidence of both mechanisms playing a role 
in RNA identification in the type III-B (Cmr) system of Thermotoga maritima.  Utilizing 
recombinantly purified Cmr complex and RNA targets generated through in vitro 
transcription, we systematically studied the role of antitag sequence in the target PFS.  We 
find that, like the PfuCmr complex, TmaCmr specifically recognizes a portion of the PFS; a 
guanosine in the first position of the PFS is an important indicator of a host-derived RNA.  
We also show that, like several Type III-A complexes, TmaCmr recognizes base pairing 




CRISPR-Cas provides prokaryotes with adaptive immunity from bacteriophage and 
other MGEs (mobile genetic elements)9.  In competition with the rapid evolution of phage, 
CRISPR-Cas systems have diversified immensely among the six types24.  These acquired 
immune systems are found in about 50% and 90% of bacteria and archaea respectively, and 
are nearly ubiquitous in hyperthermophiles6,16. Of these, about 25% and 34% respectively are 
Type III systems16. This type includes four subtypes: Types III-A and III-D which utilize the 
Csm effector complex, and Types III-B and III-C, which utilize the Cmr complex16.  
Whereas most types of CRISPR-Cas target foreign DNA, Type III systems (Csm/Cmr) 
utilize a transcription-coupled mechanism to degrade both RNA and DNA10.   
By coupling targeting to transcription and by degrading both forms of nucleic acid, 
Type III systems provide an extremely robust immune response and yet tolerate potentially 
beneficial MGEs.  MGEs may contribute genes that provide a fitness advantage to the 
bacterium, such as genes that inhibit other phage invasions or increase bacterial 
pathogenicity and survival49.  Incorporation of spacers from viral genes that are harmful to 
the bacterium, such as those that promote viral replication or bacterial lysis, allows for 
coexistence of bacterium and MGE until it becomes detrimental for bacterial survival50.  
Furthermore, as RNA complementary to the crRNA activates Type III effectors (and 
therefore the CRISPR array in the genome is not targeted), specific PAM sequences are not 
required for foreign DNA identification.  Instead, Type III systems rely on the identity of the 
target RNA PFS for recognition of self RNA to prevent inappropriate activation of the 
interference machinery; anti-tag sequence in the crRNA-adjacent PFS prohibits activation of 
the Type III immune response23.  This allows for broad targeting relative to that afforded by 
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Types I and II, where a mutation in the PAM sequence of the target allows the phage to 
escape targeting10.   
Like all CRISPR-Cas systems, the leader sequence upstream of the CRISPR array 
directs transcription of pre-crRNA as one RNA containing multiple spacers; in Type III 
systems, this pre-crRNA is processed by Cas621.  While in other CRISPR-Cas types the 
repeat sequence readily forms stem-loops that are identified by Cas6, many Type III repeats 
are predicted to form weak secondary structures, if any51.  It is thought that in these cases 
Cas6 is able to stabilize a hairpin that is otherwise too unstable to form51.  Cleavage by Cas6 
at the base of the stem-loop leaves an eight-nucleotide segment of repeat sequence (the 
crRNA tag) at the 5’ end of each spacer27.  Further processing by other unknown nucleases 
may cleave the repeat sequence (or a portion of it) from the 3’ end of the spacer28.  Other Cas 
proteins, such as Csm2 and Csm5 in Type III-A, are often required for crRNA maturation52. 
The Csm/Cmr complex forms around the crRNA, with the length of the crRNA 
dictating the number of filamenting subunits (Csm3/Cmr4)21,28.  Complexes often assemble 
around crRNAs that vary in length, with one added molecule each of Csm3/Cmr4 and 
Csm2/Cmr5 for every six additional nucleotides; however the function of these differently 
sized crRNAs and complexes is unknown21,52,53.  Upon identification of an RNA target that is 
complementary to the crRNA spacer, the RNase domain in each Csm3/Cmr4 subunit cleaves 
the RNA, producing a six-nucleotide cut pattern36,54–56.  A foreign RNA target also induces a 
conformational change that allows for activation of two domains of the Cas10 subunit33,53,57;  
the HD domain is activated to degrade ssDNA22,36,37, and the Palm domain initiates 
production of a secondary messenger (cyclic oligoadenylate, or cOA) by the Cas10 Palm 
domain31,32.  Figure 4B provides a schematic summary of Type III interference. 
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It was originally thought that Csm complexes targeted DNA38,58, while Cmr 
complexes targeted RNA54–56. Once thought to be a difference among subtypes, this 
discrepancy likely arose due to a difference in experimental methods; initial studies 
performed with Csm complexes were done in vivo, while those with Cmr complexes were 
done in vitro.  Both Csm and Cmr have since been shown to degrade both RNA and DNA, 
resulting in a unified model of transcription-coupled targeting22,36,37. 
In both Csm and Cmr, DNA cleavage activation is inhibited upon identification of 
self RNA targets; in both cases, an RNA target containing an antitag PFS does not allow 
Cas10 activation36–38,59–61.  However the method by which this inhibition occurs may differ 
between Csm and Cmr.  Type III-A (Csm) studies from Staphylococcus epidermidis (Sep) 
have indicated that base pairing between the crRNA tag and the target antitag prevents Cas10 
activation33,38.  Structural studies indicate that base pairing is possible between the antitag 
and tag sequences at positions -2 and -5; tag positions -1 and -6 to -8 are unavailable for base 
pairing and are therefore not likely to be involved in RNA identification in these systems53,57. 
 By contrast, a study of a Type III-B (Cmr) system from Pyrococcus furiosus (Pfu) 
suggests that the first three nucleotides of the PFS are recognized specifically to allow or 
prevent Cas10 activation37. It is currently unclear if the mechanism of discrimination is 
subtype-specific (i.e. that Type III-A/Csm systems use base pairing, while Type III-B/Cmr 
systems use sequence specificity) or if either mechanism can be utilized by any given Type 
III system. 
In this study, we investigate the mechanism of self and nonself target discrimination 
by the Cmr complex from Thermotoga maritima (Tma).  Utilizing recombinantly purified 
TmaCmr complex, we tested targets containing varying positions of antitag sequence within 
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the PFS to understand the mechanism of target discrimination.  We determined that antitag 
sequence in positions -1 to -3 of the PFS is minimally sufficient to inhibit DNA cleavage by 
TmaCmr.  Alternatively, antitag sequence in positions -2 to -5 is also sufficient for inhibition 
of DNA cleavage.  We find that, like the PfuCmr complex, TmaCmr specifically recognizes a 
portion of the PFS; a guanosine in the first position of the PFS is an important indicator of a 
host-derived RNA.  We also show that, like several Type III-A complexes, TmaCmr 
recognizes base pairing between the PFS and the crRNA tag (at positions -2 to -5) to identify 
self transcripts.   
Results 
Activation of DNA cleavage requires a noncomplementary 3’ protospacer flanking sequence 
Activation of DNA cleavage by Type III systems requires pairing of the crRNA with 
an RNA protospacer and is regulated by the PFS.  DNA cleavage is blocked in all Type III 
systems if the RNA target contains an anti-tag sequence in the PFS22,36–38,59–61 (Figure 7A).  
However, the precise role of the PFS in the activation of DNA cleavage is unclear.  Our lab 
previously reported that RNA targets lacking flanking sequences can activate DNA cleavage 
by TmaCmr36, but in other Type III systems, a PFS that lacks antitag sequence is required for 
activation59,60.  To investigate this further, we monitored cleavage of ssDNA by TmaCmr in 
the presence of a series of RNA targets.  Our lab also previously showed that TmaCmr 
cleaves ssDNA after thymine bases36; thus for simplicity of readout, we used a ssDNA 
oligonucleotide with a single thymine at its center. The TmaCmr:crRNA complex was 
assembled from recombinant proteins (Figure 6A) and crRNA generated by in vitro 
transcription and subsequent processing with recombinant TmaCas6 (Figure 6B-C).  We 
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incubated labeled ssDNA substrate with the TmaCmr:crRNA complex and excess RNA 
target composed of a complementary protospacer and 10 nucleotides of noncomplementary 
sequence at each flank. DNA cleavage was monitored by denaturing polyacrylamide gel 
electrophoresis (PAGE) followed by autoradiography.  The expected cleavage product was 
observed after one minute at 80°C when all the required components (crRNA, TmaCmr, 
complementary RNA target, and Mn2+) were present (Figure 7B).   
The fraction of ssDNA cleavage was next monitored over time in the presence of 
RNA targets containing no 3’ PFS, a noncomplementary PFS, or a complementary (antitag) 
PFS.  An RNA target containing noncomplementary 3’ and 5’ flanks (the same RNA target 
used in the previous experiment, Figure 7B) triggered rapid cleavage of the DNA; all DNA 
was cleaved within 60 seconds. However, RNA targets lacking a PFS (either with or without 
a 5’ flank) triggered slower DNA cleavage, with less than half the DNA being cleaved after 
90 seconds.  Almost no DNA cleavage was observed in the presence of an RNA target 
containing an antitag PFS (Figure 7C). These results indicate that DNA cleavage by the 
TmaCmr complex is partially activated by a complementary RNA protospacer, but a PFS that 
lacks antitag sequence is required for full activation. 
The bound RNA target temporally regulates the DNase activity of Csm/Cmr 
complexes; cleavage and subsequent dissociation of the RNA target deactivates the 
DNase22,36,37.  To determine if RNA cleavage altered the rate of DNA cleavage in our 
experiments, we monitored RNA cleavage by performing the same reaction with 5’ end-
labeled the RNA targets (rather than ssDNA).  Under these conditions, where the RNA target 
is in ~8-fold excess of the TmaCmr complex, we observed that less than 5% of each RNA 
target is cleaved after 60 seconds (Figure 8A-C). We also compared the rates of DNA 
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cleavage by wild-type TmaCmr complex and by a TmaCmr complex formed with the Cmr4 
D26A mutant, which can bind to but cannot cleave RNA36, and found no significant 
differences (Figure 8 D-F).  Thus, we concluded that the difference in the rate of DNA 
cleavage in the presence of the different RNA targets was not due to a difference in the rate 
of RNA cleavage. Finally, to determine if all RNA targets can bind to the complex, Brian 
Learn measured the affinity of TmaCmr for each target using electrophoretic mobility shift 
assays (EMSAs).  He concluded that all targets are bound with similar affinities (apparent 
KDs ~0.3 nM) (Figure 9).  Therefore, RNA binding does not explain the observed differences 
in DNA cleavage.  Together these data indicate that the PFS directly regulates the DNase 
activity of TmaCmr, likely via conformational changes in the Cas10 subunit as observed in 
Type III-A systems33,53,57.  
Positions -1 to -3 of the RNA target are important for regulating DNA cleavage 
 Data collected in vivo in Pfu have suggested a role for the specific sequence of 
positions -1 to -3 of the RNA target in activating Type III-B immunity37.  To first determine 
which positions of the PFS regulate the DNase activity of TmaCmr, we measured the extent 
of DNA cleavage in the presence of RNA targets containing varying complementarity to the 
crRNA tag.  Beginning with a target containing an antitag sequence, which triggered almost 
no DNA cleavage (Figure 10A, Target 1), we removed complementarity one base at a time, 
making cumulative changes from position -8 to -1 (Figure 10A, Targets 2-8). With these 
targets, we observed no increase in the extent of DNA cleavage until only positions -1 and -2 
contained antitag sequence (that is, positions -3 to -8 were noncomplementary), whereupon 
DNA cleavage was triggered to nearly the same extent as a target containing a 
noncomplementary PFS (Figure 10A, Targets 7 and 9). Moreover, a target with 
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noncomplementary sequence positions -1 to -3 triggered DNA cleavage to the same extent as 
the target with a fully noncomplementary PFS (Figure 10A, Target 10). These observations 
suggest that, like targets of PfuCmr37, the three nucleotides of the PFS adjacent to the 
protospacer (positions -1 to -3 of the target) are important for regulating the DNase activity 
of the TmaCmr complex.   
 The study performed in PfuCmr indicated that at least half of all possible sequences 
in positions -1 to -3 activated DNA cleavage37.  To determine which sequences allow DNase 
activity in TmaCmr, we generated a series of RNA targets containing all possible sequences 
in positions -1 to -3.  In each of these 64 targets, the sequence of positions -4 to -8 is 
noncomplementary to the crRNA tag. The extent of DNA cleavage permitted by each target 
was measured as before. Nearly every triplet sequence allowed DNA cleavage (Figure 10B).  
The only sequence in positions -1 to -3 that failed to trigger DNA cleavage was the antitag 
sequence (GUU).  DNA cleavage was reduced in the closely related AUU sequence (Figure 
10B).  
A guanine at position -1 of the RNA target helps to prevent DNA cleavage 
 In the previous experiment, a GUU sequence in positions -1 to -3 of the RNA target 
failed to activate DNA cleavage while UUU, CUU and AUU sequences at the same positions 
all activated DNA cleavage (Figure 10B), indicating the importance of position -1.  However, 
structural data of Csm complexes shows that positions -1 of the crRNA and PFS are 
displaced by a loop of Csm4 (homolog of Cmr3) and therefore cannot base pair53,57.  
Together, these observations suggest that a guanine at position -1, and not base pairing, helps 
to prevent activation of DNA cleavage.  To confirm this, we generated crRNA variants with 
each nucleotide at position -1 (Wild-type C-1, variants C-1U, C-1A, and C-1G).  We then 
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compared the amount of DNA cleaved by TmaCmr containing these crRNAs when activated 
by the above-mentioned RNA targets (those with GUU, AUU, CUU, and UUU in positions -
1 to -3), thereby testing every combination of nucleotides in position -1.  Regardless of 
crRNA sequence, and therefore base pair potential, a guanine at position -1 of the RNA 
target activated little DNA cleavage (Figure 11A).  Conversely, robust DNA cleavage was 
triggered when position -1 of the target contained a cytosine, uracil, or to a lesser extent 
adenine (Figure 11A).  All crRNA variants were functional as TmaCmr bound to each was 
capable of robust DNA cleavage in the presence of the RNA target with uracil at position -1 
(Figure 11A). These results indicate that in TmaCmr, position -1 of the RNA target cannot 
base pair with the crRNA tag and that a guanine (the nucleotide present in repeats) at this 
position helps to prevent DNA cleavage. 
 We noted that a GUU sequence in positions -1 to -3 inhibits DNA cleavage, even 
when the rest of the PFS is noncomplementary to the crRNA tag (Figure 10). However, if 
either of the uracils in position -2 or -3 of this target is substituted for any other base, DNA 
cleavage is activated (Figure 10B).  We wondered if substitution of the guanine in an antitag 
PFS would also permit DNA cleavage.  We generated a series of target RNAs, beginning 
with a target with an antitag PFS and removing antitag sequence in a stepwise and 
cumulative fashion from position -1 to position -8.  Upon testing these targets ability to 
activate DNA cleavage of TmaCmr, we found that substituting a cytosine at position -1 of an 
otherwise complementary PFS was not enough to restore DNA cleavage, but did increase the 
extent of cleavage slightly (Figure 11B, Target 2).   However, further removal of antitag 
sequence fully restored DNase activity (Figure 11B, Targets 3 to 8). We therefore conclude 
that a guanine at position -1 is not sufficient or necessary to prevent DNA cleavage. 
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Base pairing at positions -2 to -5 of the crRNA prevents DNase activation 
 After establishing a role for guanine in position -1 in preventing DNase activation, we 
wanted to investigate the role of the other positions in the 3’ flank.  The data presented above 
already indicates that positions -2 and -3 are important.  Structural studies in Type III-A 
systems have shown that positions -2 to -5 of the crRNA tag are exposed and form base pairs 
with antitag sequence, but positions -1 and -6 to -8 are buried and thus cannot form base 
pairs53,57. In vivo data also indicate the importance of base pairing at positions -2 to -5 for 
regulating DNA cleavage by Csm30,38. To test if positions -2 to -5 are important for 
regulation of the DNase activity of TmaCmr, we measured the extent of DNA cleavage 
triggered by RNA targets with varying degrees of complementarity in these positions.  We 
found that an RNA target with a PFS complementary to only the positions buried in the Type 
III-A structures (-1 and -6 to -8) permitted the same extent of DNA cleavage as a target with 
no anti-tag sequence (Figure 12A, Target 2). RNA targets with antitag sequence at positions -
2 to -5 and either guanine or cytosine at position -1 inhibited DNA cleavage (Figure 12A, 
Targets 3 and 4). Consistent with our earlier observations (Figure 11B), the target with a 
guanine at position -1 inhibited DNA cleavage to a greater extent than the target with a 
cytosine at the same position. We conclude that, as in Type III-A systems30,38,53,57, positions -
2 to -5 of the RNA target regulate the DNase activity of TmaCmr.  
 To understand how much antitag sequence is needed between positions -2 and -5 to 
inhibit DNA cleavage, we designed RNA targets that only contain anti-tag sequence at three 
of these four positions. We tested these targets for their ability to activate DNA cleavage by 
TmaCmr and found that each triggered robust DNA cleavage (Figure 12A, Targets 5-8) 
similar to that of an RNA target containing no antitag sequence (Figure 12A, Target 9). Thus, 
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if position -1 is a cytosine, all four bases in this region must have antitag sequence in order to 
inhibit DNA cleavage.  
 Given that a guanine in position -1 helps to prevent activation of DNA cleavage, we 
also generated a series of RNA targets containing a guanine at position -1 and one or two 
bases of antitag sequence in positions -2 to -5. Analysis of DNA cleavage in the presence of 
these targets revealed that RNAs with antitag sequence in positions -4 and -5 permitted more 
DNase activity than those with antitag sequence in positions -2 and -3 (Figure 12B, Targets 
2-11).  Thus, positions -2 and -3 are more important for blocking the DNase activity of 
TmaCmr than positions -4 and -5. 
 These data implicate positions -2 to -5 of the RNA target in regulating the DNase 
activity of TmaCmr. However, they do not address whether the identities of the nucleotides 
in this region are important or if these nucleotides base pair with the crRNA tag. To explore 
these two possibilities, we generated four variant crRNAs, each with a single nucleotide 
substitution in one position between -2 and -5. We then monitored DNA cleavage by the 
TmaCmr complex containing wild-type and variant crRNAs in the presence of RNA targets 
that harbor compensatory substitutions in the same position, resulting in complementarity in 
all four positions. Robust DNA cleavage is triggered in the presence of all of these targets 
with wild-type crRNA (Figure 12C).  In agreement with the base-pairing model, DNA 
cleavage was inhibited when base pairing was possible (Figure 12C).  All crRNA variants 
were functional as each TmaCmr:crRNA complex robustly cleaved DNA in the presence of 





  The ability to accurately identify target sequences as foreign-derived is essential for 
avoiding host genome degradation in CRISPR-Cas systems.  Types I, II, and V utilize 
specific PAM sequences to recognize foreign targets.  Due to this specificity, the host 
genome is well protected but a point mutation in the PAM sequence of a viral target permits 
phage escape.  Thus the foreign target identification of these systems sacrifices targeting 
robustness in order to prioritize host genome protection.  In order to combat this issue, some 
systems (thus far only described in Type I) are able to acquire additional spacers from phages 
that have mutated their target or PAM sequence through a mechanism called primed 
acquisition17,19.  By contrast, it seems that the broad targeting specificity displayed by Type 
III systems leads them to prioritize viral destruction over genome protection, which ensures 
protection from phage but carries a fitness cost30. 
 The Type III Csm/Cmr complex targets RNA rather than DNA and as such does not 
require a PAM sequence.  The PFS on the RNA target dictates whether the transcript is of 
host or foreign origin.  Data from Type III-A in vivo studies demonstrate that base pairing 
between an antitag PFS and the crRNA tag indicates a host transcript38, and structural studies 
show that this pairing deactivates the Cas10 subunit53,57.  Alternatively, data from in vivo 
studies of a Type III-B system suggests that the sequence in the first 3 positions of the RNA 
target PFS indicates the origin of the transcript37.  While it was previously unclear if these 
mechanisms are specific to the subtypes in which they’ve been described, we present 
evidence of a Type III-B system utilizing both mechanisms of transcript identification. 
 A previous study from our lab showed that DNase activation in TmaCmr was 
achieved with an RNA target lacking a PFS36, while studies from other systems have 
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indicated that a nonself PFS is required for activation59,60.  We demonstrate that while a 
target lacking a PFS partially activates DNA cleavage by TmaCmr, full activation requires a 
noncomplementary PFS (Figure 7C).  With a target lacking a PFS, the rate of DNA cleavage 
is slower than RNA cleavage36; however with a nonself PFS, complete DNA cleavage occurs 
before RNA degradation (Figure 7C, Figure 8A, D).  As RNA targets in the cell would 
contain PFSs, this target and the DNase activity it licenses are more biologically relevant.  A 
more rapid rate of DNA degradation is consistent with the model that RNA cleavage and 
dissociation serves as a temporal control of DNase activity. 
  We demonstrate the importance of positions -1 to -3 of the target for self 
identification (Figure 10).  Like in PfuCmr37, antitag sequence in these first three nucleotides 
of the PFS is sufficient to deactivate the DNA cleavage of TmaCmr.  However, unlike 
PfuCmr37, other sequences in these positions do not deactivate DNA cleavage (Figure 10B).  
We also showed that the nucleotide in the first position of the antitag PFS (a guanosine at 
position -1) is specifically recognized (Figure 11A).  This is in agreement with structural 
models that indicate inhibition of base pairing in this position of the crRNA tag and RNA 
target antitag33,53,57.  Furthermore, we present evidence that a guanosine is not required for 
DNA cleavage inhibition; if positions -2 to -5 contain antitag sequence, DNase activity is 
prohibited (Figure 11B, 12A).  Like in SepCsm, these positions are recognized by base 
pairing (Figure 12C). 
 These data demonstrate that TmaCmr utilizes both of the mechanisms that have been 
proposed for Type III target identification.  This represents consistency between the III-A 
and III-B subtypes, rather than the previously proposed difference.  Originally, Type III-A 
systems were thought to target DNA38,58, while Type III-B systems were proposed to target 
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RNA54–56; however, later work established a unified model by demonstrating that both Csm 
and Cmr degrade DNA and RNA22,36,37.  Perhaps the data presented in this study support 
another unified model for Type III systems; it is conceivable that effector complexes from all 
Type III subtypes are able to use both base pairing and protein recognition for target 
identification. The experimental setups of the two studies that proposed the conflicting 
mechanisms37,38 may have biased the results and therefore allowed the researchers to 
overlook this possibility.  Alternatively, perhaps target identification falls on a spectrum.  
That is, some Type III effectors may recognize antitag targets through base pairing alone 
(e.g. SepCsm38) while others may recognize these based on sequence specificity (PfuCmr37), 
and yet others utilize both mechanisms (TmaCmr) to different extents.  Further work in more 
















Figure 6. TmaCmr protein and RNA generation.  (A) SDS-PAGE gels of recombinantly purified 
TmaCmr2-6 WT (left), TmaCmr2-6 D26A (middle), and TmaCmr1 (right).  L indicates ladder (NEB 
P7712).  (B) Urea-PAGE gel of crRNA and target RNA.  L indicates ladder (NEB N0364).  Synthetic 
crRNA was included as a control to confirm appropriate size after crRNA transcription and 
processing by TmaCas6. (C) Schematic of crRNA production.  A double-stranded DNA template was 
first transcribed by T7 RNA Polymerase and the resulting RNA was processed by TmaCas6 to 
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Figure 7.  DNA cleavage by TmaCmr is transcript-dependent. (A) DNA cleavage in Type III 
CRISPR-Cas systems is activated by a transcript with a 3’ protospacer flanking sequence (PFS) that 
lacks complementarity to the crRNA (shown in green).  RNA targets containing an antitag PFS 
(shown in pink) fail to activate DNA cleavage.  Structural studies indicate that positions -2 to -5 of 
the crRNA are available for base pairing.  (B) Urea-PAGE analysis of DNA cleavage by TmaCmr.  
First lane (M) contains markers of substrate and expected product.  5’ radiolabeled DNA was 
incubated with (+) or without  (-) TmaCmr 1-6, crRNA, Mn2+, and target RNA for 60 seconds at 80° 
C.  Target “c” and “n” indicate RNA protospacers complementary or noncomplementary to the 
crRNA spacer region, respectively.  (C) Quantification of DNA cleavage by TmaCmr complex over 
time upon activation with RNA targets containing various 3’ and 5’ flanks. RNA targets represented 
by green circles have a noncomplementary PFS, while purple triangles represent targets without a 
PFS (dark purple includes a 5’ flank, light purple lacks a 5’ flank), and pink squares represent targets 
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Figure 8.  Verification of target RNA persistence. Green (panels A, D) indicates a noncomplementary 
PFS, pink (panels B, F) indicates an antitag PFS, and purple (panels C, E) indicates no PFS. (A, B, C) 
Representative Urea-PAGE showing persistence of RNA target after incubation with TmaCmr for 60 
and 90 seconds under DNA cleavage conditions.  M indicates marker generated by 5’ radiolabeling 
expected cleavage products (synthetic) of a 55 nucleotide substrate.  (D, E,F) Quantified time courses 
of DNA cleavage with wild-type (dashed lines and filled shapes) and RNA cleavage mutant D26A 















































































































Figure 9*.  Verification of RNA target binding by TmaCmr. Binding curves with representative 
EMSA and binding constants of TmaCmr with RNA targets with the following PFS. (A) 
noncomplementary, (B) antitag, (C) no PFS.  *All Figure 9 experiments and quantification were 
performed by Brian Learn. 
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Figure 10.   Importance of RNA target positions -1 to -3 in self target identification.  (A) 
Quantification of DNA cleavage by TmaCmr complex when activated by RNA targets with various 
positions of antitag sequence in the PFS.  Black letters indicate positions of antitag sequence.  (B) 
Heat map of TmaCmr DNA cleavage upon activation with RNA targets with all sequences in 
positions -1 to -3.  All PFS contain noncomplementary sequence in positions -4 to -8.  Dark purple 
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Figure 11.  Role of RNA target position -1 in target identification. (A) Quantification of DNA 
cleavage by TmaCmr complex. Position -1 WT or mutant crRNAs were paired with RNA targets 
containing U, C, A, and G at position -1 and DNA cleavage was quantified.  All targets contain the 
same sequence of 5’-UUAGGUA-3’ in positions -2 to -8. Black letters indicate positions of antitag 
sequence.  (B) Quantification of DNA cleavage by TmaCmr complex when activated by transcripts 


















Figure 12.  Role of target positions -2 to -5 in self target identification.  (A,B) Quantification of DNA 
cleavage by Cmr complex when activated by RNA targets with various positions of antitag sequence.  
Black letters indicate antitag sequence. (C) Quanitification of DNA cleavage by TmaCmr complex.  
Target RNAs with antitag sequence in three of four positions from -2 to -5 were paired with WT 
crRNA (*) or a crRNA mutated such that the target gained full complementarity in this region. (D) 




Materials and Methods 
Expression and purification of recombinant proteins 
 TmaCmr2-6 complex was made by expressing each subunit individually and pooling all 
cells for purification.  TmaCmr3 (codon-optimized), TmaCmr4 (wild-type or D26A), and 
TmaCmr5 were previously individually cloned into pRSFDuet-1 and TmaCmr6 was 
previously cloned into pHAT236.  TmaCmr2 was codon-optimized and cloned into 
pRSFDuet-1 (Novagen) as well.  These vectors were transformed individually into 
T7Express cells (NEB).  1 L of each (2L TmaCmr6) was grown with appropriate antibiotics 
at 37 °C to OD600 = 0.4 in Luria-Bertani (LB) media followed by induction with 200 μM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and overnight growth at 20 °C.  Cells were 
pelleted and resuspended together in lysis buffer [1M KCl, 20 mM tris pH 8.0, 10 mM 
imidazole, 1 mM tris(2-carboxyethyl)phosphine (TCEP)] with 1 μM E-64, 0.1 μM 
phenylmethylsulfonyl fluoride (PMSF), 1.7 μM bestatin, 2.5 μM pepstatin A, and 1 mM each 
ATP and MgCl2.  The cells were then lysed using a microfluidizer.  The lysate was heat 
treated in an 80 °C water bath for ten minutes, then clarified by centrifugation.  This sample 
was passed over a 5 mL immobilized metal affinity chromatography (IMAC) column (Bio-
Rad) charged with nickel sulfate and equilibrated with lysis buffer.  After washing with 20 
column volumes (CV) lysis buffer, the sample was eluted [500 mM KCl, 20 mM tris pH 8.0, 
250 mM imidazole, 1 mM TCEP] and further purified by size exclusion (HiLoad 26/60 S200 
column, GE Healthcare) in gel filtration buffer [350 mM KCl, 20 mM tris pH 8.0, 1 mM 
TCEP] (Figure 6A).  
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Cmr1 (Figure 6A) and Cas6 were cloned into pHAT2 and purified separately as 
described above without heat treatment. 
His6-P266L T7 RNA polymerase
62 was expressed in T7Express cells.  1L was grown 
to OD600 = 0.3 at 37 °C, induced with 200 μM IPTG, and grown overnight at 20 °C.  The 
cells were pelleted and resuspended in T7RNAP lysis buffer [250 mM NaCl, 10 mM 
imidazole, 20 mM HEPES pH 7.0, 10 mM dithiothreitol (DTT), and 5% glycerol] with 1 μM 
E-64, 0.1 μM PMSF, 1.7 μM bestatin, 2.5 μM pepstatin A.  Cells were lysed using a 
microfluidizer and clarified by centrifugation.  The sample was added to 3 mL of nickel-
charged Profinity™ IMAC resin (Bio-Rad) in T7RNAP lysis buffer and gently rocked at 4 
°C for 30 minutes.  The supernatant was removed and the resin was washed with 25 CV lysis 
buffer.  The protein was then eluted [250 mM NaCl, 250 mM imidazole, 20 mM HEPES pH 
7.0, 10 mM DTT, and 5% glycerol]. 
RNA generation  
All RNAs under 45 nucleotides were purchased (Sigma), while longer RNAs were 
synthesized by in vitro transcription.  5μM complementary DNA templates (Sigma) were 
annealed [50 mM NaCl, 10 mM tris pH 8.0, and 1 mM ethylenediaminetetraacetic acid 
(EDTA)] by slow cooling from 95 °C to room temperature.  100 nM dsDNA was then 
incubated with 5 mM each rNTP, 15 mM MgCl2, 0.1 mg/mL P266L T7 RNA polymerase, 
and transcription mix [25 mM tris pH 8.0, 2 mM spermidine, 40 mM DTT] for 2 – 3 hours at 
37 °C.  
 crRNAs were transcribed as described above.  Following transcription, RNAs were 
treated with Cas6 to trim the 5’ repeat sequence: the transcription reaction was incubated 
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with 200 nM Cas6 for 20 minutes at 80 °C in Cas6 cleavage buffer [65 mM KCl, 20 mM 
HEPES pH 7.0, 20 mM EDTA, and 10% glycerol] (Figure 6B-C). 
Transcripts (including processed crRNAs) were then gel extracted, ethanol 
precipitated, and resuspended in RNA storage solution (Thermo Fisher) with 1 unit Ribolock 
RNase inhibitor (Figure 6B). 
Radiolabeling of oligonucleotides 
DNA substrate (Sigma) and synthetic RNAs were gel purified and radiolabeled with 
1-2 pmol [γ32P]ATP (Perkin-Elmer) by incubating 200 nM DNA in 1x T4 polynucleotide 
kinase (PNK) buffer with 10 units T4 PNK (NEB) at 37 °C for 30 minutes, followed by heat 
inactivation at 65 °C for 20 minutes. 
Prior to radiolabeling, 5’ ends of transcripts were dephosphorylated by incubating 200 
nM RNA in 1x CutSmart buffer with 1 unit shrimp alkaline phosphatase (rSAP) (NEB) for 
30 minutes at 37 °C, followed by a 20 minute heat inactivation at 75 °C.  10 units T4 PNK, 
1x PNK buffer and 2 pmol [γ32P]ATP were added and the reaction incubated at 37 °C for 30 
minutes, followed by heat inactivation for 20 minutes at 65 °C.  The transcripts were then gel 
extracted, ethanol precipitated, and resuspended in RNA storage solution. 
DNA cleavage assays 
TmaCmr complex was first formed by incubating crRNA, TmaCmr1, and TmaCmr2-
6 at 80 °C for 20 minutes in reaction buffer [100 mM KCl, 50 mM HEPES pH 7.0, 1 mM 
TCEP, and 1 mM MnCl2].  25 nM TmaCmr complex was used in cleavage reactions.  
Following complex formation, 95 nM unlabeled DNA substrate and 5 nM 5’ radiolabeled 
DNA were added.  Reactions were initiated upon addition of 200 nM RNA (or RNA storage 
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solution in no transcript controls) and quenched [90% formamide, 2.5% glycerol, 0.01% 
SDS, 0.01% bromophenol blue, 0.01% xylene cyanol, and 1 mM EDTA] after 1 minute 
unless otherwise indicated. These samples were then run on 15% polyacrylamide urea gels 
and visualized by phosphorimaging (FujiFilm FLA-7000).  Images were quantified using 
Image Gauge (FujiFilm) and data analysis was done in Prism (GraphPad Software) and Excel 
(Microsoft).  All data points are the average of at least three replicates and error bars 
represent standard error of the mean. 
RNA cleavage assays 
 
RNA cleavage assays were performed with the same protocol as described above for 
DNA cleavage but with 5 nM 5’ radiolabeled target RNA, 195 nM unlabeled target RNA, 
and 100 nM unlabeled DNA.  Synthetic RNAs of expected products were radiolabeled and 
used as markers to confirm appropriate product size. 
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CHAPTER 3: TARGET MISMATCH TOLERANCE IN A TYPE III-B 
CRISPR-CAS SYSTEM 
 
Type III CRISPR-Cas systems offer robust protection from phage by utilizing a 
CRISPR-RNA (crRNA)-guided effector complex to degrade foreign RNA and DNA.  These 
systems are more robust than other CRISPR-Cas types in part because they are activated by 
more target PFS sequences, as described in Chapter 2.  Additionally, they seem to tolerate 
more mismatches.  For example, unlike other types of CRISPR-Cas interference, duplex 
formation between the crRNA and the target RNA does not require a seed sequence in Type 
III systems; mismatches are tolerated across the entire spacer:protospacer duplex.  While 
other types typically tolerate fewer than four mismatches, a study of SepCsm demonstrated 
that many mismatches do not affect Type III-A immunity and only with extensive 
mismatching (five or more nucleotides) in the PFS-adjacent segment of the target is 
immunity weakened.  It is unknown if this level of mismatch tolerance is universal among all 
Type III systems, or if it is subtype- or species-specific. 
Here, we present support for high mismatch tolerance among Type III systems.  
Utilizing recombinantly purified Cmr complex and RNA targets generated through in vitro 
transcription, we studied the requirement for base pairing between segments of the crRNA 
spacer and the target protospacer.  We find that, like the SepCsm complex, TmaCmr 
activation is significantly reduced by a target that contains five mismatched nucleotides at the 
PFS-adjacent segment (segment 1).  We also provide evidence that a target activates DNA 
cleavage even with significant regions of mismatching outside of segment 1 as long as it is 
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still able to bind to the TmaCmr complex.  These data support findings in Type III-A systems 
and extend the defining characteristic of mismatch tolerance to Type III-B. 
Introduction 
 
CRISPR-Cas interference complexes are guided by their crRNAs to complementary 
nucleic acid targets.  Activation of the effector relies upon complementarity between the 
target sequence and the crRNA as well as identification of the target as foreign and not host-
derived.  CRISPR-Cas Types I, II, and V rely upon the use of a PAM sequence for foreign 
nucleic acid identification15; however, as discussed in Chapter 1, Type III systems rely on the 
lack of antitag sequence in the target PFS for self target identification and are therefore 
activated by more target sequences.  This reduces the potential for viral escape mutants in 
Type III systems30. 
CRISPR-Cas types require different levels of complementarity between the target 
protospacer and crRNA spacer sequences.  The effectors of Types I, II, V, and VI have been 
shown to rely upon a seed sequence for duplex formation and any mismatches in this region 
prevent further base pairing (and therefore complex activation)10.  Outside of the seed region, 
mismatches are often tolerated to an extent, particularly in the PAM-distal region of the 
protospacer.  Cascade (Type I) is able to target DNA containing four or fewer mismatched 
positions outside of the seed region63.  Cas9 (Type II) can tolerate only one or two 
mismatches, perhaps due in part to fewer positions of the crRNA being available for base 
pairing to begin with64.  Cas12a (Type Va) is sensitive to single mismatches in the PAM-
proximal end but can tolerate double mismatches in the PAM-distal end40.  Cas13a (Type 
VIa) tolerates one or two mismatches, depending on the position40.  Further mismatching 
between the target and crRNA allow for viral escape in each of these cases. 
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Type III systems likely do not require a seed sequence; data on the SepCsm (Type III-
A) system indicate that mismatches are tolerated in all regions of the protospacer21,30.  In fact, 
extensive accumulation of mismatches is tolerated throughout the protospacer in SepCsm, 
and only with contiguous mismatches in the first five nucleotides of the protospacer is 
immunity weakened30.   Escape mutants were undetectable (below the limit of detection, one 
in 1010) if an essential gene was targeted by Type III-A, while one in 109 viral particles 
escaped Type II-A immunity30.  Deletion of the targeted region seems to be the only escape 
from Type III-A systems, which is rarely possible as targeted phage genes are typically 
essential; thus Type III-A CRISPR-Cas can cause extinction of a targeted phage30. 
It is unclear if tolerance for target mismatches is universal for all subtypes of Type III 
systems.  We were particularly curious if Type III-B systems are capable of cleaving DNA 
given mismatched RNA targets.  To address this, we generated RNA targets containing 
various levels of complementarity to the crRNA and tested their ability to activate 
recombinantly purified TmaCmr.  Crystal structures of Cmr have revealed that, as in 
Cascade, a loop is inserted between every sixth nucleotide of the crRNA and target RNA 
duplex, flipping out the bases at these positions25,53,57.  We defined each of these five-base 
pair regions as a segment and introduced changes in the target RNA at one segment at a time.  
We found that all segment mismatches were tolerated except segment 1 (the PFS-proximal 
region).  However, contiguous mismatching in this segment is required to inactivate DNA 
cleavage by TmaCmr, supporting the notion that Type III systems do not require a seed30.  
We also demonstrate that outside of segment 1, extensive mismatching is tolerated so long as 




Segments of five mismatches are tolerated except in the PFS-proximal segment 
Immunity in Type III systems seems to be highly tolerant of mismatches between the 
crRNA and RNA protospacer30. The structure of the crRNA:RNA target duplex in Type III 
complexes is arranged into segments of five base pairs separated by disrupted one base 
gaps25,53,57.  We generated RNA targets (via in vitro transcription) in which we introduced 
five nucleotide blocks of mismatches at each of these segments in order to determine where 
mismatches might be tolerated for DNA cleavage by recombinantly purified TmaCmr 
complex (Figure 7). We monitored DNA cleavage by TmaCmr in the presence of these RNA 
targets and found that mismatches within the PFS-proximal segment 1, which includes the 
five nucleotides at the most 3’ end of the protospacer (the most 5’ end of the crRNA spacer) 
prevented DNA cleavage (Figure 13A, Target 2) However, an RNA target containing any 
other mismatched segment fully activated DNA cleavage (Figure 13A, Targets 3-7).  Brian 
Learn performed EMSAs to determine that the RNA target with mismatched segment 1 
bound to TmaCmr with the same affinity as a fully complementary target (Figure 9) and a 
target with a mismatched segment 6 (Figure 13C). The RNA target itself was cleaved to the 
same extent (<5% after 60 seconds, Figure 13D) as a fully complementary target (Figure 8A) 
We conclude that base pairing in segment 1 of a bound RNA target is important for the 
activation of DNA cleavage.  
To see how many base pairs are needed for DNase activation, we also monitored 
DNA cleavage in the presence of RNA targets containing single point or accumulating 
mismatches within segment 1, finding that as few as one to two base pairs in this segment is 
sufficient to activate DNA cleavage (Figure 14). These observations show that base pairing 
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in segment 1 is necessary to activate DNA cleavage, but every position need not be base 
paired for activation.  
Mismatching in other segments is tolerated until target no longer binds 
To determine how many mismatched segments are tolerated for DNA cleavage 
activation, we tested RNA targets containing an increasing number of mismatched segments, 
starting at segment 6 (the 5’ end of the RNA protospacer). We determined that as the number 
of mismatched segments increases, DNA cleavage decreases.  When only segments 1 and 2 
remain complementary, DNA cleavage does not proceed above background (DNA cleavage 
in the presence of a fully mismatched RNA protospacer) (Figure 13A).  Brian Learn again 
performed EMSAs to assess binding of TmaCmr to these targets, as the complex is likely to 
have a lower affinity for targets that contain extensive mismatches to the crRNA.  He showed 
that targets which failed to activate DNA cleavage were also poorly bound by TmaCmr 
(Figure 13 C).  We therefore concluded that as long as a target contains a complementary 
segment 1 and can bind to the TmaCmr complex, it will activate DNA cleavage. 
Discussion 
  
Most CRISPR-Cas systems are highly specific for targets containing full 
complementarity to the crRNA spacer.  Most importantly in Types I, II, V, and VI is 
complementarity to the seed region; a lack of base pairing between the crRNA and target 
within this seed region prevents effector activation in these types10.  Outside of this seed, 
these types are typically only able to tolerate between one and four mismatches40,63,64.  A lack 
of a seed sequence has been suggested for some Type III systems (with evidence presented 
from SepCsm), in which extensive mismatches are tolerated in all regions of the protospacer; 
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in fact, this system is so tolerant of mismatches that the most probable way for a phage to 
escape targeting is to delete the target from its genome30. Evidence from SepCsm suggests 
that some amount of base pairing in the first ten nucleotides nearest to the PFS and crRNA 
tag is important for immunity; yet an effect on immunity is only detected with five or more 
mismatches in this region30.  However, there is insufficient evidence to understand if 
extensive mismatch tolerance is a universal characteristic of Type III targeting.   
Here we demonstrate that the TmaCmr complex also tolerates extensive mismatching.  
Like SepCsm30, base pairing is most important in the segment nearest the PFS but DNA 
cleavage is still activated with targets that contain up to four of five mismatches in this first 
segment (Figure 13A, Figure 14).  Although a target with mismatched segment 1 does not 
activate DNA cleavage, this target is still bound (Figure 13B); thus this segment does not 
constitute a seed region in which complementarity is required for binding.  We also 
demonstrate that mismatched nonself targets activate DNA cleavage as long as the 
protospacer maintains enough complementarity (including segment 1) to bind to the complex 
(Figure 13A, B).  This supports the finding that phage mutants are unable to escape from 
Type III-A targeting by SepCsm30 and suggests that this may be a common feature of Type 
III systems. 
The findings presented in Chapters 2 and 3 demonstrate that TmaCmr exhibits broad 
targeting capabilities and that this may be a common feature of all Type III systems.  
Whereas Types I and II often must acquire multiple spacers for each target for effective 
interference, Type III systems only require one spacer30.  The broad targeting capabilities of 
Type III systems ensures phage elimination but has been demonstrated to transfer a fitness 
cost to the host30.  Spacer acquisition has been proposed to occur less frequently in Type III 
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systems than in other CRISPR-Cas systems, perhaps in part due to this fitness cost30.  
Additionally, acquisition has not yet been detected in Type III systems, and acquisition 
machinery is absent in many Type III-B loci28.  Thus it is unclear how spacers are acquired, 
but evidence suggests that once acquired, these spacers provide Type III CRISPR-Cas with a 







Figure 13.  Tolerance of protospacer mismatches.  (A) Quantification of DNA cleavage by Cmr 
complex activated by targets containing protospacers that are mismatched to the crRNA in one or 
multiple segments.  Segments are defined by the five-nucleotide stretches of base pairs within the 
structure of the crRNA-target duplex. All targets contain a noncomplementary PFS. (B, C) 
Quantification of Cmr complex binding to mismatched targets (B) 2 and 7 and (C) 8, 9, 10, and 11 
from panel A.  These experiments (Panels B and C) and quantifications were performed by Brian 
Learn. (D) Representative Urea-PAGE showing persistence of RNA target after incubation with 
TmaCmr for 60 and 90 seconds under DNA cleavage conditions.  M indicates marker generated by 5’ 
radiolabeling expected cleavage products (synthetic) of a 55 nucleotide substrate.  
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Figure 14.  Tolerance of single or multiple mismatches in segment 1. Quantification of DNA cleavage 
by TmaCmr upon activation with targets containing one or more mismatches within segment 1. 
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